IDARUCIZUMAB FOR REVERSAL OF THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY, OR INTERVENTIONSCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Journal of the American College of Cardiology|2016Cited by 2
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventionsCharles V. Pollack, Jeffrey I. Weitz, Robert Dubiel et al.|Journal of Thrombosis and Haemostasis|2015Cited by 2